Keryx Biopharmaceuticals, Inc. (KERX) Reviewed By Analysts

Institutional investors now hold around $568 million or 64.6% in KERX stock. Keryx Biopharmaceuticals (NASDAQ:KERX) has risen 13.56% since July 13, 2016 and is uptrending. It has underperformed by 3.14% the S&P500. It was reported on Jul, 13 by Barchart.com. We have $6.51 PT which if reached, will make NASDAQ:SVBI worth $6.03M less.

Isramco, Inc., together with its subsidiaries, is an independent oil and natural gas company. It has a 43.68 P/E ratio. The Firm operates through two divisions: Oil and Gas Exploration and Production Segment, and Production services Segment. The firm presently has a $8.75 target price on the biopharmaceutical company's stock. Therefore 40% are positive.

By having an overview of the Income statement for Keryx Biopharm Inc (NASDAQ:KERX) the Revenue for the trailing twelve months is 36.98 Million.

05/08/2017 - Keryx Biopharmaceuticals, Inc. had its " rating reiterated by analysts at Maxim Group.

Paris Hilton's Boyfriend Chris Zylka Gets Disney Inspired Tattoo of Her Name
The heiress added: "You are my best friend, my other half & made me see that fairytales exist & dreams really do come true". Paris Hilton and her boyfriend Chris Zylka celebrated their anniversary this week in her fave, Ibiza.

Keryx Biopharmaceuticals, Inc.'s ROA is -80.14%, while industry's average is -5.35%. A stock price loss will yield a negatively weighted alpha. FBR Capital downgraded the stock to "Market Perform" rating in Tuesday, August 2 report. Analysts are expecting EPS growth rates to be at -28.40% this quarter and EPS estimate for next year reflect 66.70% growth rate.

08/02/2016 - Keryx Biopharmaceuticals, Inc. had its " rating reiterated by analysts at Cowen. ValuEngine lowered shares of Keryx Biopharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, June 2nd. Maxim Group reaffirmed a "buy" rating and set a $7.00 price objective on shares of Keryx Biopharmaceuticals in a research note on Monday, May 1st. The $7.75 level represents at least another 3.49% downside for the stock from its current price. On average, equities analysts forecast that Keryx Biopharmaceuticals will post ($0.69) EPS for the current year.

By historical standards, Keryx Biopharmaceuticals, Inc. remains a cheap stock. The company has market cap of $10.81 billion. The Firm is engaged in the manufacture, development and commercialization of products for use in treating human diseases. A negative earnings surprise will usually result in a decline in share price. The Company's marketed product, Auryxia, which is an orally available, absorbable, iron medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

It tells an investor how quickly a company is increasing its revenues. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.29 average brokerage recommendation.

Steel Dynamics, (STLD) Lifted at Longbow Research
Analysts are expecting EPS growth rates to be at 389.30% this quarter and EPS estimate for next year reflect 7.20% growth rate. The stock witnessed 19.03% gains, 0.17% gains and -52.56% declines for the 1-month, 3-month and 6-month period, respectively.

05/05/2015 - Keryx Biopharmaceuticals, Inc. was upgraded to " by analysts at Zacks. 19 funds opened positions while 31 raised stakes. Nationwide Fund Advsr has 49,640 shares. Commonwealth Equity Svcs Inc has invested 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX). Everpoint Asset Mngmt Ltd holds 60,000 shares or 0.01% of its portfolio.

So the company lags the analysts estimate by $-0.01/share showing a surprise of -5%. Alliancebernstein Limited Partnership holds 149,340 shares. Aperio Lc owns 11,362 shares or 0% of their U.S. portfolio.

Several analysts have released their opinion on Keryx Biopharmaceuticals, Inc. It increased, as 9 investors sold KERX shares while 32 reduced holdings. About 52,881 shares traded or 492.11% up from the average. Da Davidson & invested in 0% or 3,500 shares. Keryx Biopharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.21. The company is expected to report EPS as high as $-0.11 and as low as $-0.19 per share. California Employees Retirement System has invested 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX).

Since January 17, 2017, it had 0 insider purchases, and 13 selling transactions for $272,912 activity. $24,608 worth of Keryx Biopharmaceuticals (NASDAQ:KERX) was sold by Madison Greg. The SEC filing shows that Adams Brian performed a sale of 641 shares. Neylan John F. had sold 6,984 shares worth $32,476 on Monday, January 30. Int Group accumulated 45,402 shares or 0% of the stock. During the same period in the previous year, the company earned ($0.39) earnings per share. The Delaware-based Blackrock Advisors Llc has invested 0% in the stock. Deutsche Bank maintained the shares of GG in report on Monday, October 5 with "Hold" rating.

Manchester United goalkeeper Johnstone completes Aston Villa loan move
The 24-year-old finished last term with Steve Bruce's side and performed well for the Midlanders in the Championship during his 22 appearances.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.